<DOC>
	<DOCNO>NCT00670566</DOCNO>
	<brief_summary>The primary objective evaluate antihypertensive efficacy fix combination Irbesartan/HydroChloroThiazide ( CoAprovel ) Chinese moderate severe hypertensive patient . The secondary objective get systolic blood pressure diastolic blood pressure goal attainment rate CoAprovel Chinese hypertensive patient .</brief_summary>
	<brief_title>Irbesartan/Hydrochlorothiazide Control Elevated Blood Pressure Target Moderate Severe Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Essential hypertensive patient Moderate severe Patients uncontrolled blood pressure ( systolic blood pressure ≥160mmHg , diastolic blood pressure ≥100mmHg untreated , systolic blood pressure ≥150mmHg , diastolic blood pressure ≥95mmHg treat monotherapy ) . Patients willing discontinue previous antihypertensive medicine Pregnant lactate woman , woman child bear potential without contraceptive method . Hypersensitivity component product sulfonamide derive substance . Secondary hypertension . Severe renal impairment ( Creatinine Clearance ≤30ml/min ) Severe hepatic impairment , biliary cirrhosis cholestasis . Refractory hypokalemia , hypercalcaemia . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>